Further evidence for the involvement of tachykinin receptor subtypes in formalin, and capsaicin models of pain in mice

Neuropeptides

Volumn 31, Issue 4, 1997, Pages 381-389

  Santos, A R S ^a   Calixto, J B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; FORMALDEHYDE; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NALOXONE; OSANETANT; PHYSALAEMIN[9 DEXTRO PROLINE SPIRO GAMMA LACTAM 10 LEUCINE 11 TRYPTOPHAN]; SAREDUTANT; TACHYKININ RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; MOUSE; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0030870332     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(97)90075-5     Document Type: Article

References (45)

1. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 1993; 73: 229-308.
2. Regoli D, Boudon A, Fauchéra J-L. Receptors and antagonists for substance P and related peptides. Pharmacol Rev 1994; 46: 551-589.
3. Maggi C A. The mammalian tachykinin receptors. Gen Pharmacol 1995; 26: 911-944.
4. Patacchini R, Maggi C A. Tachykinin receptors and receptor subtypes. Arch Int. Pharmacodyn Ther 1995; 329: 161-184.
5. Perkins M, Dray A. Novel pharmacological strategies for analgesia. Ann Rheum Dis 1996; 55: 715-722.
6. Henry J L. Effects of substance P on functionally identified units in cat spinal cord. Brain Res 1976; 144: 439-451.
7. Bowden J J, Garland A M, Baluk P et al. Direct observation of substance P induced internalization of neurokinin-1 (NK1) receptors at sites of inflammation. Proc Natl Acad Sci USA 1994; 91: 8964-8968.
8. Dray A, Urban L, Dickenson A. Pharmacology of chronic pain. Trends Pharmacol Sci 1994; 15: 190-197.
9. Bertrand C, Geppetti P. Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease. Trends Pharmacol Sci 1996; 17: 255-259.
10. Guard S, Watson S P. Tachykinin receptor types: classification and membrane signalling mechanisms. Neurochem Int 1991; 18: 149-165.
11. Mussap C J, Geraghty D P, Burcher E. Tachykinin receptors: a radioligand binding perspective. J Neurochem 1993; 6: 1987-2009.
12. Donnerer J, Amann R. The inhibition of neurogenic inflammation. Gen Pharmacol 1993; 24: 519-529.
13. Germonpré P R, Joos G F, Pauwels R A. Characterization of the neurogenic plasma extravasation in the airways. Arch Int Pharmacodyn Ther 1995; 329: 185-203.
14. Dray A. Mechanism of action of capsaicin-like molecules on sensory neurons. Life Sci 1992; 51: 1759-1765.
15. Seguin L, Marouille-Girardon L, Millan M J. Antinociceptive profiles of non-peptidergic neurokinin-1 and neurokinin-2 receptor antagonists, a comparison to other classes of antinociceptive agent. Pain 1995; 61: 325-343.
16. 1 receptor antagonist, on the formalin test in the rat. Neurosci Lett 1993; 161: 57-59.
17. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-110.
18. 2 kinin receptors in formalin-induced nociceptive response in the mouse. Br J Pharmacol 1993; 110: 193-198.
19. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 1987; 30: 103-114.
20. Sakurada T, Katsumata K, Tan-No K, Sakurada S, Kisara K. The capsaicin test in mice for evaluating tachykinin antagonists in the spinal cord. Neuropharmacology 1992; 31: 1279-1285.
21. 2 bradykinin receptor antagonist NPC 18688 in mice. Br J Pharmacol 1996; 117: 552-558.
22. Teixeira R M, Santos A R S, Ribeiro S J, Calixto J B, Rae G A, De Lima T C M. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 1996; 311: 7-14.
23. Vaz Z R, Cechinel Filho V, Yunes R A, Calixto J B. Antinociceptive action 2-(4-Bromobenzoyl)-3-Methyl-4,6-Dimethoxy Benzofuran, a novel Xanthoxyline derivate on chemical and thermal models of nociception in mice. J Pharmacol Exp Ther 1996; 278: 304-312.
24. Chapman V, Dickenson A H. The effect of intrathecal administration of RP 67580, a potent neurokinin-1 antagonist, on nociceptive transmission in the rat spinal cord. Neurosci Lett 1993; 157: 149-152.
25. 1 receptor antagonist, in the mouse formalin and capsaicin tests. Neurosci Lett 1993; 151: 142-145.
26. Yamamoto T, Yaksh T L Stereospecific effects of a nonpeptedic NK1 selective antagonist, CP 96345: antinociception in the absence of motor dysfunction. Life Sci 1991; 49: 1955-1963.
27. Nagahisa A, Asai R, Kanai Y et al. Non specific activity of (±)CP 96345 in models of pain and inflammation. Regul Pept 1993; 46: 433-436.
28. Garret C, Carruette A, Fardin V et al. Antinociceptive properties and inhibition of neurogenic inflammation with potent SP antagonists belonging to perhydroisoindolones. Regul Pept 1993; 46: 24-30.
29. 1 receptor antagonists CP 96345 and RP 67580. J Biol Chem 1992; 267: 25668-25671.
30. 3 receptor. Life Sci 1994; 56: 27-32.
31. 3 receptor expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1995; 274: 148-154.
32. Patacchini R, Barthò L, Holzer P, Maggi C A. Activity of SR 142801 at peripheral tachykinin receptors. Eur J Pharmacol 1995; 278: 17-25.
33. Sakurada T, Katsumata K, Manome Y et al. Antinociceptive effects in the formalin and capsaicin tests after intrathecal administration of substance P analogues in mice. Eur J Pharmacol 1993; 242: 47-52.
34. Carter R C. Topical capsaicin in the treatment of cutaneous disorders. Drug Dev Res 1991; 22: 109-103.
35. Dray A. Neuropharmacological mechanism of capsaicin and related substances. Biochem Pharmacol 1992; 44: 611-615.
36. Ren K, Williams G M, Ruda M A, Dubner R. Inflammation and hyperalgesia in rats neonatally treated with capsaicin: effects on two classes of nociceptive neurons in the superficial dorsal horn. Pain 1994; 59: 287-300.
37. Malmberg A B, Yaksh T L. Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats. J Neurosci 1995; 15: 2768-2776.
38. Post C, Folkers K. Behavioural and antinociceptive effects of intrathecally injected substance P analogues in mice. Eur J Pharmacol 1985; 113: 335-343.
39. Tan-No K, Sakurada T, Yamada T, Sakurada S, Kisara K. Spantide-induced antinociception in the opioid mechanism. Regul Pept 1993; 46: 343-345.
40. Levine J D, Fields H L, Basbaum A I. Peptides and the primary afferent nociceptor. J Neurosci 1993; 13: 2273-2286.
41. Otsuka M, Yanagisawa M. Pain and neurotransmitter. Cell Mol Neurobiol 1990; 10: 293-302.
42. Bannon M J, Brownschidle L A, Tian Y et al. Neurokinin-3 receptors modulate dopamine cell function and alter the effects of 6-hydroxydopamine. Brain Res 1995; 695: 19-24.
43. Ravard S, Betschart J, Fardin V, Flamand D, Blanchard J C. Differential ability of tachykinin NK-1 and NK-2 agonists to produce scratching and grooming behaviours in mice. Brain Res 1994; 651: 199-208.
44. Rupniak N M J, Williams A R. Differential inhibition of foot tapping and chomadacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. Eur J Pharmacol 1994; 265: 179-183.
45. Quartara L, Rovero P, Maggi C A. Peptide based tachykinin NK2 receptor antagonists. Med Res Rev 1995; 15: 139-155.